

PRESS NEWS

Gradientech receives funding from the Horizon 2020 SME Instrument program

Uppsala, March 26, 2018. Gradientech receives funding in the latest call for the phase 1 of the Horizon SME Instrument program. The successful application received high scores and was completed in close collaboration with GAEU Consulting, a professional consultancy firm specialist in EU subsidies and grants. Gradientech is a Swedish biotech and diagnostic company developing QuickMIC™, the next generation ultra-rapid antibiotic susceptibility testing (AST) system for appropriate and rapid treatment of sepsis. The SME Instrument phase 1 funding will support the continued market driven development with focus on exploring the US market in addition to finalizing the clinical validation plans for the intended CE-marking of the system.

For further information, please contact:

Sara Thorslund, CEO

Tel: +46 736 29 35 80, email: sara.thorslund@gradientech.se

TO THE EDITORS

About Gradientech

Gradientech is a Swedish biotech and diagnostic company based on innovative microfluidic product development. We provide precision assays and software solutions for high-quality analysis of cell behavior in response to gradients of signalling molecules. Driven by the increased global prevalence of antibiotic resistance, Gradientech is developing its microfluidic platform QuickMIC™ - the most rapid IVD system for antibiotic susceptibility testing of sepsis patients.